Company Description
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA.
Scilex Holding Company is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2011 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Henry Ji |
Contact Details
Address: 960 San Antonio Road Palo Alto, California 94303 United States | |
| Phone | 650 516 4310 |
| Website | scilexholding.com |
Stock Details
| Ticker Symbol | SCLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001820190 |
| CUSIP Number | 80880W205 |
| ISIN Number | US80880W2052 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Henry H. Ji Ph.D. | Chief Executive Officer, President and Executive Chairman |
| Stephen Ma | Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary and Director |
| Dr. Suketu D. Desai Ph.D. | Interim Chief Technical Officer and Senior Vice President |
| Gigi DeGuzman | Vice President and Chief People Officer |
| Suresh K. Khemani | Senior Vice President, Chief Commercial Officer and GM of Scilex Pharma |
| Dr. Dmitri V. Lissin M.D. | Senior Vice President of Clinical Development and Medical Affairs and Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 8-K | Current Report |
| Nov 28, 2025 | 4 | Statement of changes in beneficial ownership of securities |
| Nov 28, 2025 | 3 | Initial statement of beneficial ownership of securities |
| Nov 24, 2025 | 424B3 | Prospectus |
| Nov 24, 2025 | 424B3 | Prospectus |
| Nov 24, 2025 | 424B3 | Prospectus |
| Nov 24, 2025 | 8-K | Current Report |